PHARMAZEUTISCHE ZUSAMMENSETZUNG MIT FUSIONSPROTEIN MIT FUSIONIERTEM TUMORPENETRIERENDEM PEPTID UND ANTI-ANGIOGENESE-MITTEL ALS WIRKSTOFF ZUR PROPHYLAXE UND BEHANDLUNG VON KREBS ODER VON ANGIOGENESEASSOZIIERTEN ERKRANKUNGEN
The present invention relates to a pharmaceutical composition containing, as an active ingredient, a fusion protein in which a tissue-penetrating peptide and an anti-vascular endothelial cell growth factor (anti-VEGF) agent are fused, for treating cancer or angiogenesis-related diseases. More specifically, the present invention relates to a use of the fusion protein for treating cancer or angiogenesis-related diseases, wherein the fusion protein improves the tissue penetrability of an anti- vascular endothelial cell growth factor agent and exerts a cancer targeting effect, thereby producing an excellent angiogenesis inhibiting effect and exhibiting a therapeutic effect on cancer showing resistance or unresponsiveness to the anti-VEGF agent.
